Latest: Watch here for details of new products and services.
- About Us
- Pharmalicensing - Open Innovation for the life sciences
- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Due Diligence
- Comparison
- Due Diligence
- Overview
- Top Applications
- Online Panel Discussions
- Request Consultation
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire
- Jobs
- Forums
- Contact Pharmalicensing
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
Pharmalicensing Ltd
is a division of
is a division of
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
Generic dossier More
This invention relates to an animal model showing several behavioral and neuropathological features of schizophrenia. More
Ladostigil, a novel cholinesterase and brain selective monoamine oxidase (MAO) inhibitor for the treatment of dementia co-morbid with depression More
Technology enable QD product opportunity available for out-license. More
The SNP identified in the SCN1A gene can be used as a genotype test to aid in the correct dosing of anti-epileptic drugs thereby avoiding debilitating adverse drug effects. More
Substitution treatment for opiod drug addiction More
Functional agonists at 5-HT2 receptors as demonstrated using Inositol Phosphate (IP3) assay with EC50 values of 300 nM or less, and Emax of at least 50% of serotonin. More
Functional antagonists at the 5 HT2A receptor using Inositol Phosphate (IP3) assay with IC50 values less than 100 nM. More
Opioid receptor blocker which reduces desire for opioids and alcohol, use in psychiatry, neurology and addition medicine. More
Your selection
Browse By
- Industry sector
- Generics
- Nutrition
- OTC/Non-Prescription
- Pediatric
- Personal Care
- Prescription
- Therapeutic target
- Addiction
- Alcoholism
- Anorexia nervosa
- Anxiety
- Bipolar disorder
- Bulimia nervosa
- Cocaine addiction
- Depression
- Mental health (other)
- Obsessive compulsive disorder
- Opioid dependency
- Panic disorder
- Phobia, social
- Post-traumatic stress disorder
- Psychosis
- Schizophrenia
- Development phase
- Early Stage
- Preclinical
- Phase I
- Phase I/II
- Phase II
- Phase III
- Phase III/IV
- Preregistration
- Registered
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us